BC Extra | Sep 13, 2016
Clinical News

Applied Genetic slides after clinical updates

Applied Genetic Technologies Corp. (NASDAQ:AGTC) fell $4.19 (32%) to $9 on Tuesday after it said enrollment was slower than expected in two Phase I/II studies of its ocular gene therapy candidates. One of the studies...
BC Week In Review | May 18, 2015
Clinical News

Applied Genetic Technologies, Pfizer preclinical data

In dogs with achromatopsia, AAV-hCNGB3 led to functional rescue of cone cells in 100% of treated eyes. The product is an adeno-associated virus (AAV) vector expressing the human cyclic nucleotide gated channel beta 3 (CNGB3)...
Items per page:
1 - 2 of 2